{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-104009","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.251173+00:00","generated_at":"2026-05-17T01:23:00.018257+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel expects to submit IGALMI at-home sNDA early Q1 2026","bullets":["Completed SERENITY At-Home Phase 3 safety trial in August 2025; positive topline data.","Correlation study completed October 2025 with positive results supporting efficacy outcomes.","sNDA submission for at-home label expansion now expected early Q1 2026 (previously no firm date).","IGALMI currently approved only for acute agitation in bipolar/schizophrenia in supervised settings."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-104009","json":"https://secwatch.observer/filing/0001104659-25-104009.json","markdown":"https://secwatch.observer/filing/0001104659-25-104009.md","text":"https://secwatch.observer/filing/0001104659-25-104009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925104009/0001104659-25-104009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925104009/tm2529774d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:23:00.018257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}